Larimar Therapeutics reported a net loss of $32.8 million ($0.30 per share) for the second quarter ended June 30, 2026, compared to a $26.2 million loss in the prior year period. The company holds $156.3 million in cash and marketable securities as of June 30, projecting a runway into the third quarter of 2027. Operational highlights include the submission of the first module of a rolling Biologics License Application (BLA) seeking accelerated approval for nomlabofusp, with completion expected in the second half of 2026. Dosing of the first patient in the global confirmatory Phase 3 study is anticipated in the third quarter of 2026. The company operates as a clinical-stage biotechnology firm developing treatments for complex rare diseases.

Larimar Therapeutics, Inc. announced on June 29, 2026, that it has submitted the first module of a rolling Biologics License Application (BLA) rolling submission to the FDA for the accelerated approval of nomlabofusp. Additionally, the following long-term open-label study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich's ataxia was reported to have yielded positive data. Larimar Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.